Latest News
Winning the HAE Global Walk
Congratulations to the Canadian HAE Community! Canadians logged the most steps to win the 2021 Global Walk for a third time. Thank you very much to all who
2021 HAE Day 🙂
Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day 🙂 by doing something extra fun. Did you go for a hike? Did you plant
TAKHZYRO: Available in Saskatchewan
HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click
HAEGARDA: Available Across Canada
We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy
TAKHZYRO now available in Newfoundland & Labrador
We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
